Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: A three-month, open-label study in community-based practices in Thailand

Journal of the Medical Association of Thailand

Volumn 88, Issue 9, 2005, Pages 1228-1235

  Wanichwecha rungruang, Boonsong ^a,b,d   Iemsomboon, Wallop ^c  

^a Glaucoma Services   (Thailand)

^b RANGSIT UNIVERSITY   (Thailand)

^c PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^d RAJAVITHI HOSPITAL   (Thailand)

Author keywords

Bimatoprost; Intraocular pressure; Ocular hypertension; Open angle glaucoma; Thailand

Indexed keywords

BIMATOPROST; EYE DROPS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EYE BURNING; EYE IRRITATION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MEDICAL PRACTICE; MONOTHERAPY; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; REDUCTION; SUBSTITUTION THERAPY; THAILAND;

AMIDES; ANTIHYPERTENSIVE AGENTS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PATIENT SATISFACTION; POPULATION SURVEILLANCE; SAFETY; THAILAND; TREATMENT OUTCOME;

EID: 31544444162     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. World Health Organization. Vision 2020: The Right to Sight. World Health Organization - Information Office, Geneva, Switzerland. 1999.
2. Wongwetsawat S. Epidemiology of Blindness and Low Vision in Thailand 1994. Thai Journal of Public Health Ophthalmology 2003; 17: 39-45.
3. Easthope SE, Perry CM. Topical bimatoprost: A review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2002; 19: 231-48.
4. Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM et al. The pharmacology of bimatoprost (Lumigan ) Surv Opthalmol 2001; 45(Suppl 4): S337-45.
5. Brubaker RF. Mechanism of action of bimatoprost (Lumigan ). Surv Ophthalmol 2001; 45(Suppl 4): S347-51.
6. Cantor LB. Bimatoprost: A member of a new class of agents, the prostamides, for glaucoma management. Expert Opin Investig Drugs 2001; 10: 721-31.
7. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci 2003; 44: 715-21.
8. Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM. Two-year double masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Opthalmol 2004; 49(Suppl 1): S45-52.
9. Whitcup SM, Cantor LB, VanDenburgh AM, Chen K. A randomized, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br J Ophthalmol 2003;87:57-62.
10. Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, VanDenburgh AM, Chen K, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002; 120: 1286-93.
11. Sherwood M, Brandt J, Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once daily and twice daily with timolol twice daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001; 45(Suppl 4): S361-6.
12. Brandt JD, VanDenburgh AM, Chen K, Whitcup SM; Bimatoprost Study Group. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: A 3-month clinical trial. Ophthalmology 2001; 108: 1023-31.
13. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM; Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressurelowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135: 55-63.
14. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM; Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001; 18: 110-21.
15. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001; 45(Suppl 4): S353-60.
16. Cantor LB, WuDunn D, Cortes A, Hoop J, Knotts S. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004; 49(Suppl 1): 312-8.
17. Noecker RJ, Earl ML, Mundorf T, Peace J, Williams RD. Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther 2003; 20: 121-8.
18. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, maskedevaluator multicenter study. Am J Ophthalmol 2003; 135: 688-703.
19. Bournias TE, Lee D, Gross R, Mattox C. Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension. J Ocul Pharmacol Ther 2003; 19: 193-203.
20. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology 2003; 110: 609-14.
21. Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther 2002; 19: 275-81.
22. Coleman Al, Lerner F, Bernstein P, Whitcup SM. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 2003; 110: 2362-8.
23. Coons SJ, Sheahan SL, Martin SS, Hendricks J, Robbins CA, Johnson JA. Predictors of medication noncompliance in a sample of older adults. Clin Ther 1994; 16: 110-7.
24. FDA Report to Congress - Reports on Postmarketing Studies. Available from: http://www.fda.gov/cber/fdama/pstmrktfdama130.htm.
25. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000; 130: 429-40.
26. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991; 111: 51-5.
27. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126: 487-97.
28. Weinreb RN. Lowering intraocular pressure to minimize glaucoma damage. J Glaucoma 2001; 10(Suppl 1): S76-7.
29. South East Asia Glaucoma Interest Group. Asia Pacific Glaucoma Guidelines. 2004.
30. Schuman JS; Brimonidine Study Groups 1 and 2. Effects of systemic -blocker therapy on the efficacy and safety of topical brimonidine and timolol. Ophthalmology 2000; 107: 1171-7.
31. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121: 48-56.
32. World Health Organization Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
33. Abelson MB, Mroz M, Rosner SA, Dirks MS, Hirabayashi D. Multicenter, open-label evaluation of hyperaemia associated with the use of bimatoprost in adults with open-angle glaucoma or ocular hypertension. Adv Ther 2003; 20: 1-13.